BEVACIZUMAB-AWWB: 4,137 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
4,137
Total FAERS Reports
89 (2.2%)
Deaths Reported
307
Hospitalizations
4,137
As Primary/Secondary Suspect
43
Life-Threatening
45
Disabilities
Prescription
Status
FDA Application: 761028 ·
First Report: 20130814 · Latest Report: 20250916
What Are the Most Common BEVACIZUMAB-AWWB Side Effects?
#1 Most Reported
Off label use
441 reports (10.7%)
#2 Most Reported
Product storage error
437 reports (10.6%)
#3 Most Reported
Circumstance or information capable of leading to medication error
346 reports (8.4%)
All BEVACIZUMAB-AWWB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 441 | 10.7% | 15 | 58 |
| Product storage error | 437 | 10.6% | 0 | 0 |
| Circumstance or information capable of leading to medication error | 346 | 8.4% | 0 | 0 |
| Hypertension | 187 | 4.5% | 4 | 13 |
| Blood pressure increased | 163 | 3.9% | 0 | 3 |
| Disease progression | 160 | 3.9% | 6 | 8 |
| Product dose omission issue | 158 | 3.8% | 0 | 0 |
| Adverse event | 143 | 3.5% | 0 | 1 |
| Platelet count decreased | 118 | 2.9% | 1 | 3 |
| Fatigue | 104 | 2.5% | 4 | 19 |
| Intercepted product administration error | 97 | 2.3% | 0 | 0 |
| Nausea | 91 | 2.2% | 3 | 11 |
| Accidental exposure to product | 89 | 2.2% | 0 | 0 |
| Malaise | 83 | 2.0% | 1 | 5 |
| Diarrhoea | 78 | 1.9% | 3 | 12 |
| Ill-defined disorder | 71 | 1.7% | 0 | 2 |
| Unevaluable event | 71 | 1.7% | 2 | 14 |
| Vomiting | 65 | 1.6% | 4 | 12 |
| Abdominal pain | 63 | 1.5% | 1 | 9 |
| Asthenia | 63 | 1.5% | 1 | 19 |
Who Reports BEVACIZUMAB-AWWB Side Effects? Age & Gender Data
Gender: 61.4% female, 38.6% male. Average age: 62.9 years. Most reports from: US. View detailed demographics →
Is BEVACIZUMAB-AWWB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2013 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 1 |
| 2018 | 3 | 0 | 1 |
| 2019 | 18 | 0 | 2 |
| 2020 | 184 | 6 | 32 |
| 2021 | 428 | 15 | 43 |
| 2022 | 538 | 15 | 46 |
| 2023 | 565 | 10 | 42 |
| 2024 | 387 | 7 | 41 |
| 2025 | 253 | 3 | 21 |
What Is BEVACIZUMAB-AWWB Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 2,584 |
| Ovarian cancer | 242 |
| Colon cancer | 179 |
| Hepatocellular carcinoma | 108 |
| Colorectal cancer | 96 |
| Glioblastoma | 78 |
| Rectal cancer | 77 |
| Age-related macular degeneration | 56 |
| Off label use | 54 |
| Adenocarcinoma of colon | 50 |
BEVACIZUMAB-AWWB vs Alternatives: Which Is Safer?
BEVACIZUMAB-AWWB vs BEVACIZUMAB-BVZR
BEVACIZUMAB-AWWB vs BEVACIZUMAB-MALY
BEVACIZUMAB-AWWB vs BEXAROTENE
BEVACIZUMAB-AWWB vs BEZAFIBRATE
BEVACIZUMAB-AWWB vs BEZLOTOXUMAB
BEVACIZUMAB-AWWB vs BGB-11417
BEVACIZUMAB-AWWB vs BICALUTAMIDE
BEVACIZUMAB-AWWB vs BICTEGRAVIR
BEVACIZUMAB-AWWB vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
BEVACIZUMAB-AWWB vs BIFIDOBACTERIUM LONGUM
Official FDA Label for BEVACIZUMAB-AWWB
Official prescribing information from the FDA-approved drug label.